ETNB
89bio Inc

1,690
Loading...
Loading...
News
all
press releases
Citi says SMid biotechs alternative to large caps as it starts coverage
Investing.com -- Citi has expanded its biopharmaceutical research coverage, initiating coverage on seven small- and mid-cap (SMid) biotechnology companies. Citi said SMid biotechs remain an attractive alternative to large-cap pharmaceutical firms, particularly amid healthcare policy uncertainties. Citi initiated coverage with Buy ratings on 89bio (NASDAQ:ETNB), price target $25. Apogee (NASDAQ:APOG), price target $95. Avidity, price target $70, BioNTech (NASDAQ:BNTX), price target $145. Kiniksa, price target $40. Kymera, price target $52
investing.com·6mo ago
News Placeholder
More News
News Placeholder
Madrigal Pharma Stock Soars Despite Novo Nordisk’s ‘Superior’ MASH Trial Results: Retail Bullish On Earnings Beat
In March, Madrigal’s Rezdiffra became the first FDA-approved treatment for MASH with moderate to advanced liver scarring.
Stocktwits·10mo ago
News Placeholder
89bio, Inc. (NASDAQ:ETNB) Receives $28.83 Consensus Target Price from Analysts
89bio, Inc. (NASDAQ:ETNB - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six brokerages that are covering the stock, MarketBeat Ratings reports. Two...
Ticker Report·1y ago
News Placeholder
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the Company or 89bio ) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization...
Globe Newswire·1y ago
News Placeholder
89bio Inc CEO Rohan Palekar Sells 52,718 Shares
Related Stocks: ETNB...
GuruFocus·1y ago
News Placeholder
89bio (NASDAQ:ETNB) Shares Down 6.8%
89bio, Inc. (NASDAQ:ETNB - Get Free Report)'s share price fell 6.8% during mid-day trading on Monday . The stock traded as low as $10.78 and last traded at $10.85. 182,176 shares traded hands during...
Ticker Report·1y ago
News Placeholder
89bio (ETNB, $10.71) price exceeded its 50-day Moving Average on April 01, 2024
This price move could indicate a change in the trend, and may be a sell signal for investors...
Tickeron - Stocks·1y ago
News Placeholder
Buy Rating Affirmed for 89bio's Pegozafermin: A Promising NASH Treatment with Strong Regulatory Endorsements
Leerink Partners analyst Thomas Smith has maintained their bullish stance on ETNB stock, giving a Buy rating on March 27. Thomas Smith has given hi...
TipRanks Financial Blog·1y ago
News Placeholder
HC Wainwright Reiterates "Buy" Rating for 89bio (NASDAQ:ETNB)
89bio (NASDAQ:ETNB Get Free Report)s stock had its buy rating reissued by stock analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They...
Zolmax·1y ago
News Placeholder
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH (fibrosis stage F2-F3) patients is enrolling and...
Globe Newswire·1y ago

Latest ETNB News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.